CAJ | 학술논문

目的探讨银杏叶提取物对HBV相关肝癌形成过程的影响.方法 99只HBV转基因小鼠随机分为对照组、高给药组、低给药组各33只,高和低给药组每天分别腹腔注射35 mg/( kg·d)、17.5 mg/(kg·d)的舒血宁注射液,对照组不做特殊处理.于12个月及18个月时进行检测.结果 (1)HBV转基因小鼠在18个月可以发生肝癌,高和低给药组肝癌发生率低,与对照组差异有统计学意义.(2)高及低给药组12个月时肝脏HBx表达强度低于对照组,18个月时HBx、p53、Bcl-2表达强度低于对照组,差异均有统计学意义.(3) Spearman相关分析表明,肝癌的发生与肝组织HBx、p53、Bcl-2表达呈一定程度正相关,r分别0.536、0.487、0.403,P均＜0.05.结论银杏叶提取物可使HBV转基因小鼠肝癌发生率显著降低,可能与其能一定程度降低HBV转基因小鼠肝脏HBx、p53、Bcl-2蛋白的表达水平有关.
목적 탐토은행협제취물대HBV상관간암형성과정적영향.방법 99지HBV전기인소서수궤분위대조조、고급약조、저급약조각33지,고화저급약조매천분별복강주사35 mg/( kg·d)、17.5 mg/(kg·d)적서혈저주사액,대조조불주특수처리.우12개월급18개월시진행검측.결과 (1)HBV전기인소서재18개월가이발생간암,고화저급약조간암발생솔저,여대조조차이유통계학의의.(2)고급저급약조12개월시간장HBx표체강도저우대조조,18개월시HBx、p53、Bcl-2표체강도저우대조조,차이균유통계학의의.(3) Spearman상관분석표명,간암적발생여간조직HBx、p53、Bcl-2표체정일정정도정상관,r분별0.536、0.487、0.403,P균＜0.05.결론 은행협제취물가사HBV전기인소서간암발생솔현저강저,가능여기능일정정도강저HBV전기인소서간장HBx、p53、Bcl-2단백적표체수평유관.
Objective To investigate the effect of extract of ginkgo biloba leaf(EGb) during the formation of HBV-related hepatocellular carcinoma ( HCC ).Methods 99 HBV transgenic mice were randomly divided into control group,high-dose group,low-dose group.High-dose group and low-dose group were intraperitoneal injected 35mg/(kg · d) and 17.5 mg/( kg · d) of the shuxuening injection.Control group without special treatment.The serological markers and immunohistochemical markers in liver tissue will be done at the first 12 months and 18 months.Results ( 1 ) HBV transgenic mice can be found HCC at the 18 months.The incidence of HCC was lower in high-dose group and low-dose group,there was statistically different among the three groups.(2) The semi-quantitative scoring of liver HBx expression was highest in the control group at the 12 months.The semi-quantitative scoring of liver HBx,p53 and Bcl-2 expression was highest in the control group at the 18 months.They all appeared statistically different among the three groups.(3) Spearman correlation analysis showed that HCC incidence and liver tissue HBx,p53,Bcl-2 expression was a certain degree of positive correlation.r was 0.536,0.487 and 0.403,P ＜ 0.05.Conclusion EGb can reduced the incidence of the HCC with HBV transgenic mice.The reason may be that the EGb can reduce liver HBx,p53,Bcl-2 protein expression in the HBV transgenic mice.